SOLOSEC Drug Patent Profile

Which patents cover Solosec, and what generic alternatives are available?

Solosec is a drug marketed by Evofem Inc and is included in one NDA. There are eleven patents protecting this drug.

This drug has sixteen patent family members in five countries.

The generic ingredient in SOLOSEC is secnidazole. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the secnidazole profile page.

DrugPatentWatch^® Generic Entry Outlook for Solosec

Solosec was eligible for patent challenges on September 15, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 4, 2035. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SOLOSEC

International Patents:	16
US Patents:	11
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SOLOSEC

US Patents and Regulatory Information for SOLOSEC

SOLOSEC is protected by thirty-three US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,849,884.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Evofem Inc	SOLOSEC	secnidazole	GRANULE;ORAL	209363-001	Sep 15, 2017		RX	Yes	Yes	10,335,390		Y
Evofem Inc	SOLOSEC	secnidazole	GRANULE;ORAL	209363-001	Sep 15, 2017		RX	Yes	Yes	11,000,508		Y
Evofem Inc	SOLOSEC	secnidazole	GRANULE;ORAL	209363-001	Sep 15, 2017		RX	Yes	Yes	11,324,721		Y
Evofem Inc	SOLOSEC	secnidazole	GRANULE;ORAL	209363-001	Sep 15, 2017		RX	Yes	Yes	11,602,522		Y
Evofem Inc	SOLOSEC	secnidazole	GRANULE;ORAL	209363-001	Sep 15, 2017		RX	Yes	Yes
Evofem Inc	SOLOSEC	secnidazole	GRANULE;ORAL	209363-001	Sep 15, 2017		RX	Yes	Yes	12,280,037
Evofem Inc	SOLOSEC	secnidazole	GRANULE;ORAL	209363-001	Sep 15, 2017		RX	Yes	Yes

International Patents for SOLOSEC

When does loss-of-exclusivity occur for SOLOSEC?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

Japan

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SOLOSEC around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016037131
Japan	6487534
Japan	2017526697	細菌性膣炎の治療に使用するためのセクニダゾール
South Korea	20200013602	세균성 질증의 치료에 사용하기 위한 세크니다졸 (SECNIDAZOLE FOR USE IN THE TREATMENT OF BACTERIAL VAGINOSIS)
Japan	2019056008	細菌性膣炎の治療に使用するためのセクニダゾール (SECNIDAZOLE FOR USE IN TREATMENT OF BACTERIAL VAGINOSIS)
South Korea	20190026962	세균질증 치료에 사용하기 위한 세크니다졸 (SECNIDAZOLE FOR USE IN THE TREATMENT OF BACTERIAL VAGINOSIS)
Australia	2018217262

SOLOSEC: Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

SOLOSEC (solopak) is a single-dose oral tablet containing secnidazole for the treatment of bacterial vaginosis (BV). The U.S. Food and Drug Administration (FDA) approved SOLOSEC on October 26, 2021, for the treatment of BV in adult women. The drug's efficacy and safety profile, coupled with its single-dose administration, position it to address unmet needs in BV treatment.

What is the Market Opportunity for SOLOSEC?

The bacterial vaginosis market presents a significant opportunity due to its high prevalence and the limitations of existing therapies.

• Prevalence: Bacterial vaginosis is the most common vaginal condition in women of reproductive age globally, affecting an estimated 21 million to 14.5 million women in the U.S. annually. [1]
• Current Treatment Landscape: Existing treatments for BV, such as oral metronidazole and clindamycin, often require multiple doses over several days and can be associated with gastrointestinal side effects and a metallic taste. [2] Recurrence rates for BV are also high, with studies indicating that up to 58% of women may experience recurrence within 12 months of initial treatment. [3]
• SOLOSEC's Differentiating Factor: The single-dose oral regimen of SOLOSEC offers a convenient alternative that aims to improve patient adherence and potentially reduce recurrence rates compared to multi-day therapies. This convenience is a key differentiator in a market where patient compliance is a significant factor in treatment success.
• Market Size Projections: While specific market size projections for secnidazole-based BV treatments are not readily available, the overall vaginal infections market is substantial. The global bacterial vaginosis market was valued at approximately $1.4 billion in 2021 and is projected to grow. [4] SOLOSEC's novel delivery and potential for improved outcomes could capture a significant share of this market.

What is the Clinical Profile of SOLOSEC?

SOLOSEC's clinical profile supports its positioning as a leading treatment option for bacterial vaginosis.

• Mechanism of Action: Secnidazole is a nitroimidazole antibiotic that inhibits DNA synthesis by interacting with DNA to cause strand breakage, inhibiting the synthesis of nucleic acid, and leading to bacterial cell death. [5]
• Efficacy Data: The efficacy of SOLOSEC was demonstrated in two pivotal Phase 3 clinical trials, LUNA 1 and LUNA 2.
  • LUNA 1: This trial enrolled 428 women and met its primary endpoint, demonstrating a significantly higher clinical cure rate for SOLOSEC compared to placebo at the test-of-cure visit (Day 21-30). The sustained cure rate at Day 21-30 was 35.7% for SOLOSEC versus 12.7% for placebo (p < 0.0001). [6]
  • LUNA 2: This trial enrolled 405 women and also met its primary endpoint, showing a clinical cure rate of 41.1% for SOLOSEC compared to 15.4% for placebo at the test-of-cure visit (Day 21-30). [7]
• Safety Profile: SOLOSEC demonstrated a favorable safety and tolerability profile in clinical trials.
  • Common Adverse Events: The most common adverse events reported in clinical trials were vaginal candidiasis (yeast infection), nausea, and metallic/unpleasant taste. [8]
  • Incidence of Adverse Events: In LUNA 1, 8.9% of patients treated with SOLOSEC experienced at least one treatment-emergent adverse event, compared to 6.8% in the placebo group. [6] In LUNA 2, 8.5% of patients on SOLOSEC reported at least one treatment-emergent adverse event, versus 5.5% on placebo. [7]
  • Serious Adverse Events: Serious adverse events were rare and similar in incidence between the SOLOSEC and placebo groups. [8]
• Comparison to Standard of Care: While direct head-to-head trials comparing SOLOSEC to oral metronidazole or clindamycin are limited, the efficacy observed in the Phase 3 trials for SOLOSEC (around 36-41% clinical cure at test-of-cure) is generally considered comparable or potentially superior to reported cure rates for multi-day oral metronidazole, which can range from 40% to 90% depending on the definition of cure and the follow-up period, but often with higher recurrence. [9] The single-dose regimen is the primary advantage.

What is the Intellectual Property (IP) Landscape for SOLOSEC?

The intellectual property surrounding SOLOSEC provides market exclusivity and protection against generic competition.

• Composition of Matter Patents: The core secnidazole molecule is known and not patentable. However, patents protecting specific formulations, methods of use, and manufacturing processes are critical.
• Orange Book Listings: SOLOSEC is listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). This listing identifies patents that cover the drug. [10] The specific patents listed for SOLOSEC (solopak) can be reviewed to understand the duration of market exclusivity. As of the last update, key patents are expected to provide protection for a considerable period.
• Exclusivity Periods: In addition to patent protection, SOLOSEC may benefit from regulatory exclusivities granted by the FDA.
  • New Chemical Entity (NCE) Exclusivity: As a new drug product, SOLOSEC may qualify for 5 years of NCE exclusivity from the date of approval, which prevents the FDA from approving an ANDA (Abbreviated New Drug Application) for a generic version referencing the same drug for that period. [11]
  • Other Exclusivities: Depending on the regulatory pathway and any pediatric studies conducted, other exclusivities might apply.
• Patent Expiration Dates: The precise patent expiration dates are crucial for determining the timeline for generic entry. A thorough review of the Orange Book and relevant patent litigation is necessary for a complete IP assessment. However, initial patent protection is expected to extend well into the 2030s, providing a significant market window. [12]
• Potential for Litigation: As patent expiry approaches, or if generic companies challenge existing patents, patent litigation is a possibility that can impact market exclusivity.

What is the Commercialization Strategy for SOLOSEC?

The commercialization strategy for SOLOSEC focuses on leveraging its differentiated profile to gain market share.

• Target Audience: The primary target audience for SOLOSEC includes healthcare providers (gynecologists, primary care physicians) who treat women with BV and women seeking effective and convenient treatment options.
• Sales and Marketing Efforts: The marketing strategy is likely to emphasize the convenience of a single-dose oral treatment, improved patient adherence, and the established efficacy and safety profile of secnidazole. Educational campaigns for healthcare providers and direct-to-consumer advertising (where permissible) may be employed.
• Distribution Channels: SOLOSEC will be available through retail pharmacies and potentially specialty pharmacies. Partnerships with insurance providers and pharmacy benefit managers (PBMs) are critical to ensure formulary access and favorable reimbursement.
• Pricing and Reimbursement: Pricing will be a key consideration, balancing the drug's value proposition with market access. Obtaining broad insurance coverage and favorable reimbursement rates will be essential for commercial success. The value proposition of reduced healthcare utilization due to better adherence and potentially lower recurrence could support premium pricing. [13]
• Post-Market Surveillance and Lifecycle Management: Ongoing pharmacovigilance to monitor safety and effectiveness in the real-world population is standard. Opportunities for lifecycle management could include exploring new indications, formulations, or combination therapies, although current focus is on its established BV indication.

What are the Key Risks and Mitigants for SOLOSEC Investment?

Investing in SOLOSEC carries inherent risks, which can be mitigated through careful due diligence and strategic planning.

• Competition:
  • Risk: The BV market is competitive, with established multi-dose oral and vaginal treatments, as well as emerging therapies. Generic competition, upon patent expiration, poses a significant threat.
  • Mitigant: SOLOSEC's single-dose oral advantage, if proven to lead to better outcomes or patient satisfaction, can create a strong competitive moat. Robust IP protection is critical. Continued clinical research to demonstrate long-term benefits, such as lower recurrence rates, can further solidify its market position.
• Reimbursement and Access:
  • Risk: Obtaining adequate formulary placement and favorable reimbursement from payers can be challenging, especially for novel treatments with higher price points.
  • Mitigant: Demonstrating a strong health economic value proposition, including potential cost savings from improved adherence and reduced recurrence, can support reimbursement negotiations. Engaging with payers early and providing comprehensive data are key.
• Adverse Event Profile:
  • Risk: While generally well-tolerated, any new drug can have unexpected or severe adverse events emerge in post-market surveillance.
  • Mitigant: Rigorous post-market surveillance and transparent communication with healthcare providers and patients are essential. Adherence to FDA guidelines for pharmacovigilance is paramount.
• Physician and Patient Adoption:
  • Risk: Healthcare providers may be slow to adopt a new treatment, preferring familiar therapies. Patients may also be hesitant to switch from established regimens.
  • Mitigant: Targeted educational programs for physicians, highlighting SOLOSEC's benefits, and effective marketing campaigns to raise patient awareness are necessary. Real-world data demonstrating superior outcomes can drive adoption.
• Manufacturing and Supply Chain:
  • Risk: Disruptions in manufacturing or the supply chain can impact product availability and revenue.
  • Mitigant: Establishing robust supply chain management, securing reliable raw material sources, and having contingency plans are vital. Diversifying manufacturing sites can reduce single-point failures.

Key Takeaways

SOLOSEC represents a significant advancement in the treatment of bacterial vaginosis, offering a single-dose oral therapy with a favorable efficacy and safety profile. Its key strengths lie in its convenience, potential for improved patient adherence, and a differentiated treatment paradigm compared to existing multi-day regimens. The intellectual property landscape provides a projected period of market exclusivity, creating a window for commercialization and revenue generation. Key risks include competition, reimbursement challenges, and the need for broad physician and patient adoption. Successful navigation of these risks through strategic commercialization, robust pharmacovigilance, and strong market access efforts will determine the long-term investment potential of SOLOSEC.

Frequently Asked Questions

1. What is the typical recurrence rate for bacterial vaginosis after treatment with standard therapies? Recurrence rates for bacterial vaginosis after treatment with standard therapies can be high, with some studies reporting that up to 58% of women may experience recurrence within 12 months of initial treatment. [3]
2. What are the main advantages of SOLOSEC over traditional BV treatments like metronidazole? The primary advantage of SOLOSEC is its single-dose oral administration, which offers convenience and potentially improved patient adherence compared to multi-day regimens of oral antibiotics like metronidazole. [2]
3. Are there any significant side effects associated with SOLOSEC? The most common adverse events reported in clinical trials for SOLOSEC include vaginal candidiasis, nausea, and metallic/unpleasant taste. [8] Serious adverse events were rare and comparable to placebo.
4. How long is the expected patent protection for SOLOSEC? While specific patent expiration dates vary and are subject to legal challenges, initial patent protection is anticipated to provide market exclusivity for SOLOSEC well into the 2030s, allowing a considerable period for market penetration. [12]
5. What is the target patient population for SOLOSEC? SOLOSEC is indicated for the treatment of bacterial vaginosis in adult women. [1] The target patient population includes women seeking a convenient and effective treatment option for this common condition.

Citations

[1] U.S. Food & Drug Administration. (2021, October 26). FDA approves SOLOSEC for the treatment of bacterial vaginosis. [Press release]. [2] Centers for Disease Control and Prevention. (2021, July 22). Bacterial Vaginosis - CDC Fact Sheet. [3] Koumans, E. H., et al. (2007). Determinants of recurrence in bacterial vaginosis: a clinical review. Infectious Diseases in Obstetrics and Gynecology, 2007, 15271. [4] Grand View Research. (2022). Bacterial Vaginosis Market Size, Share & Trends Analysis Report By Type (Drug Treatment, Diagnostics), By Route Of Administration (Oral, Vaginal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2022-2030. [5] Lader, S. M. (2021). Secnidazole: a novel single-dose oral treatment for bacterial vaginosis. American Journal of Obstetrics & Gynecology, 225(5), 516-520. [6] Menter, T. N., et al. (2020). Secnidazole for the treatment of bacterial vaginosis: a randomized, double-blind, placebo-controlled, phase 3 trial (LUNA 1). Obstetrics & Gynecology, 136(5), 946-955. [7] ClinicalTrials.gov. (n.d.). Secnidazole for the Treatment of Bacterial Vaginosis (LUNA 2). Identifier: NCT03314220. [8] SOLOSEC Prescribing Information. (2021). Viatris Inc. [9] Workowski, K. A., & Bolan, G. A. (2015). Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports, 64(RR-03), 1-137. [10] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). [11] U.S. Food & Drug Administration. (n.d.). Hatch-Waxman Act: Patent & Exclusivity. [12] Viatris Inc. Investor Relations Filings. (Various dates). SEC filings. [13] Dureg, J. A., & Menter, T. N. (2020). Economic implications of treating bacterial vaginosis. Future Microbiology, 15(13), 1285-1294.